143 related articles for article (PubMed ID: 37351980)
1. The Efficacy and Safety of Ramucirumab in Heavily Pretreated Advanced Hepatocellular Carcinoma.
Chen YH; Tsai CH; Chen YY; Wang CC; Wang JH; Hung CH; Kuo YH
Anticancer Res; 2023 Jul; 43(7):3203-3212. PubMed ID: 37351980
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
3. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
Kanogawa N; Ogasawara S; Maruta S; Iino Y; Obu M; Ishino T; Ogawa K; Yumita S; Iwanaga T; Unozawa H; Nakagawa M; Fujiwara K; Sakuma T; Fujita N; Kojima R; Kanzaki H; Koroki K; Kobayashi K; Inoue M; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Koma Y; Azemoto R; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):70. PubMed ID: 36906542
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
9. Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Sugimoto R; Motomura K; Ooho A; Aratake Y; Ueda A; Senju T; Tanaka Y; Yada M; Tanaka K; Kuwano A; Morita Y; Nagasawa S; Ooe M; Mutsuki T; Yoshimoto T; Yamashita N; Nakashima M; Hioki T; Koyanagi T; Higuchi N; Nakamura T; Harada S; Tanaka M; Tada S; Satoh T; Uchimura K; Kuniyoshi M; Nakamuta M; Kohjima M;
Intern Med; 2022; 61(21):3157-3164. PubMed ID: 36328582
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
[TBL] [Abstract][Full Text] [Related]
13. [Ramucirumab Treatment for Unresectable Advanced Hepatocellular Carcinoma-A Review of Clinical Trial Data and Real-World Evidence in Japan].
Jin L; Tanizawa Y; Kuzuya T
Gan To Kagaku Ryoho; 2023 Jul; 50(7):799-807. PubMed ID: 37496225
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Finn RS; Yau T; Hsu CH; De Toni EN; Goyal L; Galle PR; Qin S; Rao S; Sun F; Wang C; Widau RC; Zhu AX
Oncologist; 2022 Dec; 27(12):e938-e948. PubMed ID: 36190331
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Amioka K; Kawaoka T; Ogawa Y; Kikukawa C; Naruto K; Yoshikawa Y; Ando Y; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Fukuhara T; Mori N; Takaki S; Tsuji K; Masaki K; Honda Y; Kouno H; Kohno H; Chayama K; Aikata H
Oncology; 2021; 99(5):327-335. PubMed ID: 33677453
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
[TBL] [Abstract][Full Text] [Related]
18. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2089-2093. PubMed ID: 32234901
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.
Shao G; Bai Y; Yuan X; Chen X; Gu S; Gu K; Hu C; Liang H; Guo Y; Wang J; Yen CJ; Lee VH; Wang C; Widau RC; Zhang W; Liu J; Zhang Q; Qin S
EClinicalMedicine; 2022 Dec; 54():101679. PubMed ID: 36247923
[TBL] [Abstract][Full Text] [Related]
20. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
Chen YH; Tsai CH; Chen YY; Wang CC; Wang JH; Hung CH; Kuo YH
BMC Cancer; 2023 Aug; 23(1):810. PubMed ID: 37644388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
